Q4 2020 13F Holders as of 31 Dec 2020
-
Type / Class
-
Equity / COM
-
Number of holders
-
107
-
Total 13F shares, excl. options
-
29.8M
-
Shares change
-
+804K
-
Total reported value, excl. options
-
$526M
-
Value change
-
+$25.1M
-
Put/Call ratio
-
0.74
-
Number of buys
-
54
-
Number of sells
-
-41
-
Price
-
$17.67
Significant Holders of Kiniksa Pharmaceuticals Intern - COM (KNSA) as of Q4 2020
130 filings reported holding KNSA - Kiniksa Pharmaceuticals Intern - COM as of Q4 2020.
Kiniksa Pharmaceuticals Intern - COM (KNSA) has 107 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.8M shares
.
Largest 10 shareholders include HILLHOUSE CAPITAL ADVISORS, LTD. (2.92M shares), BAKER BROS. ADVISORS LP (2.8M shares), VANGUARD GROUP INC (2.54M shares), AMERIPRISE FINANCIAL INC (2.37M shares), BlackRock Inc. (2.19M shares), PICTET ASSET MANAGEMENT LTD (2.05M shares), STATE STREET CORP (1.58M shares), ArrowMark Colorado Holdings LLC (1.16M shares), JANUS HENDERSON GROUP PLC (1.13M shares), and CITADEL ADVISORS LLC (1.06M shares).
This table shows the top 107 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.